Octopamine

Last Updated: September 28 2022

A metabolite of synephrine, Octopamine is a stimulant compound that is also thought to have minor fat burning effects. Banned by WADA due to its stimulatory properties, the direct fat burning claims may not be relevant and are effectively untested in humans.

Octopamine is most often used for

What else is Octopamine known as?
Note that Octopamine is also known as:
  • Norsynephrine
  • p-hydroxyphenylethanolamine
  • β-hydroxytyramine
  • Norphen
  • Norsympatol
  • norfenefrine
Examine Database: Octopamine
What works and what doesn't?

Unlock the full potential of Examine

Get started

Don't miss out on the latest research

Become an Examine Insider for FREE to stay on top of the latest nutrition research, supplement myths, and more

    References
    1.^Li B1, Tsing S, Kosaka AH, Nguyen B, Osen EG, Bach C, Chan H, Barnett JExpression of human dopamine beta-hydroxylase in Drosophila Schneider 2 cellsBiochem J.(1996 Jan 1)
    6.^David JC, Coulon JFOctopamine in invertebrates and vertebrates. A reviewProg Neurobiol.(1985)
    7.^Thevis M1, Koch A, Sigmund G, Thomas A, Schänzer WAnalysis of octopamine in human doping control samplesBiomed Chromatogr.(2012 May)
    10.^Ichikawa M1, Ryu K, Yoshida J, Ide N, Kodera Y, Sasaoka T, Rosen RTIdentification of six phenylpropanoids from garlic skin as major antioxidantsJ Agric Food Chem.(2003 Dec 3)
    14.^Brown CM1, McGrath JC, Midgley JM, Muir AG, O'Brien JW, Thonoor CM, Williams CM, Wilson VGActivities of octopamine and synephrine stereoisomers on alpha-adrenoceptorsBr J Pharmacol.(1988 Feb)
    15.^Ibrahim KE, Couch MW, Williams CM, Fregly MJ, Midgley JMm-Octopamine: normal occurrence with p-octopamine in mammalian sympathetic nervesJ Neurochem.(1985 Jun)
    17.^Premont RT1, Gainetdinov RR, Caron MGFollowing the trace of elusive aminesProc Natl Acad Sci U S A.(2001 Aug 14)
    18.^Bunzow JR1, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DKAmphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptorMol Pharmacol.(2001 Dec)
    19.^Xie Z1, Vallender EJ, Yu N, Kirstein SL, Yang H, Bahn ME, Westmoreland SV, Miller GMCloning, expression, and functional analysis of rhesus monkey trace amine-associated receptor 6: evidence for lack of monoaminergic associationJ Neurosci Res.(2008 Nov 15)
    20.^Hengstmann JH, Konen W, Konen C, Eichelbaum M, Dengler HJBioavailability of m-octopamine in man related to its metabolismEur J Clin Pharmacol.(1975)
    21.^Hengstmann JH, Konen W, Konen C, Eichelbaum M, Dengler HJThe physiological disposition of p-octopamine in manNaunyn Schmiedebergs Arch Pharmacol.(1974)
    22.^D'Andrea G1, Nordera G, Pizzolato G, Bolner A, Colavito D, Flaibani R, Leon ATrace amine metabolism in Parkinson's disease: low circulating levels of octopamine in early disease stagesNeurosci Lett.(2010 Jan 29)
    23.^Andrew R1, Best SA, Watson DG, Midgley JM, Reid JL, Squire IBAnalysis of biogenic amines in plasma of hypertensive patients and a control groupNeurochem Res.(1993 Nov)
    25.^Youdim MB1, Finberg JPNew directions in monoamine oxidase A and B selective inhibitors and substratesBiochem Pharmacol.(1991 Jan 15)
    27.^James MI, Midgley JM, Williams CMThe metabolism and biosynthesis of (+/-)-o-octopamine and (+/-)-o-synephrine in the ratJ Pharm Pharmacol.(1983 Sep)
    28.^Medana C1, Calza P, Giancotti V, Dal Bello F, Aragno M, Baiocchi CStudy of the photocatalytic transformation of synephrine: a biogenic amine relevant in anti-doping analysisAnal Bioanal Chem.(2013 Jan)
    29.^Brandau K, Axelrod JThe biosynthesis of octopamineNaunyn Schmiedebergs Arch Pharmacol.(1972)
    30.^Ibrahim KE, Midgley JM, Crowley JR, Williams CMThe mammalian metabolism of R-(-)-m-synephrineJ Pharm Pharmacol.(1983 Mar)
    31.^Kleinau G1, Pratzka J, Nürnberg D, Grüters A, Führer-Sakel D, Krude H, Köhrle J, Schöneberg T, Biebermann HDifferential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonistsPLoS One.(2011)
    32.^Carpéné C1, Galitzky J, Fontana E, Atgié C, Lafontan M, Berlan MSelective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cellsNaunyn Schmiedebergs Arch Pharmacol.(1999 Apr)
    33.^Fregly MJ, Kelleher DL, Williams CMAdrenergic activity of ortho-, meta-, and para-octopaminePharmacology.(1979)
    34.^Airriess CN1, Rudling JE, Midgley JM, Evans PDSelective inhibition of adenylyl cyclase by octopamine via a human cloned alpha 2A-adrenoceptorBr J Pharmacol.(1997 Sep)
    36.^Cheng JT1, Tsai JTOctopamine: an endogenous blocker of dopamine D-1 receptorsAdv Exp Med Biol.(1991)
    38.^Cheng JT1, Hsieh-Chen SCOctopamine relaxes rabbit jejunal smooth muscle by selective activation of dopamine D1 receptorsNaunyn Schmiedebergs Arch Pharmacol.(1988 Oct)
    42.^D'Andrea G1, D'Arrigo A, Dalle Carbonare M, Leon APathogenesis of migraine: role of neuromodulatorsHeadache.(2012 Jul-Aug)
    43.^D'Andrea G1, Granella F, Leone M, Perini F, Farruggio A, Bussone GAbnormal platelet trace amine profiles in migraine with and without auraCephalalgia.(2006 Aug)
    44.^D'Andrea G1, Terrazzino S, Leon A, Fortin D, Perini F, Granella F, Bussone GElevated levels of circulating trace amines in primary headachesNeurology.(2004 May 25)
    45.^D'Andrea G1, D'Amico D, Bussone G, Bolner A, Aguggia M, Saracco MG, Galloni E, De Riva V, Colavito D, Leon A, Rosteghin V, Perini FThe role of tyrosine metabolism in the pathogenesis of chronic migraineCephalalgia.(2013 Aug)
    46.^D'Andrea G1, Ostuzzi R, Francesconi F, Musco F, Bolner A, d'Onofrio F, Colavito DMigraine prevalence in eating disorders and pathophysiological correlationsNeurol Sci.(2009 May)
    47.^D'Andrea G1, Ostuzzi R, Bolner A, Francesconi F, Musco F, d'Onofrio F, Colavito DStudy of tyrosine metabolism in eating disorders. Possible correlation with migraineNeurol Sci.(2008 May)
    48.^Headache Classification Subcommittee of the International Headache SocietyThe International Classification of Headache Disorders: 2nd editionCephalalgia.(2004)
    49.^Visentin V1, Morin N, Fontana E, Prévot D, Boucher J, Castan I, Valet P, Grujic D, Carpéné CDual action of octopamine on glucose transport into adipocytes: inhibition via beta3-adrenoceptor activation and stimulation via oxidation by amine oxidasesJ Pharmacol Exp Ther.(2001 Oct)
    50.^Pizzinat N1, Marti L, Remaury A, Leger F, Langin D, Lafontan M, Carpéné C, Parini AHigh expression of monoamine oxidases in human white adipose tissue: evidence for their involvement in noradrenaline clearanceBiochem Pharmacol.(1999 Dec 1)
    51.^Morin N1, Lizcano JM, Fontana E, Marti L, Smih F, Rouet P, Prévot D, Zorzano A, Unzeta M, Carpéné CSemicarbazide-sensitive amine oxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytesJ Pharmacol Exp Ther.(2001 May)
    52.^Piwkowska A1, Rogacka D, Angielski S, Jankowski MHydrogen peroxide induces activation of insulin signaling pathway via AMP-dependent kinase in podocytesBiochem Biophys Res Commun.(2012 Nov 9)
    53.^Marti L1, Morin N, Enrique-Tarancon G, Prevot D, Lafontan M, Testar X, Zorzano A, Carpéné CTyramine and vanadate synergistically stimulate glucose transport in rat adipocytes by amine oxidase-dependent generation of hydrogen peroxideJ Pharmacol Exp Ther.(1998 Apr)
    54.^Flechtner-Mors M1, Jenkinson CP, Alt A, Adler G, Ditschuneit HHIn vivo alpha(1)-adrenergic lipolytic activity in subcutaneous adipose tissue of obese subjectsJ Pharmacol Exp Ther.(2002 Apr)
    55.^Lafontan M1, Barbe P, Galitzky J, Tavernier G, Langin D, Carpéné C, Bousquet-Melou A, Berlan MAdrenergic regulation of adipocyte metabolismHum Reprod.(1997 Oct)
    58.^Fontana E1, Morin N, Prévot D, Carpéné CEffects of octopamine on lipolysis, glucose transport and amine oxidation in mammalian fat cellsComp Biochem Physiol C Toxicol Pharmacol.(2000 Jan)
    60.^Alhasso A1, Glazener CM, Pickard R, N'dow JAdrenergic drugs for urinary incontinence in adultsCochrane Database Syst Rev.(2005 Jul 20)
    65.^David JC1, Coulon JF, Cavoy A, Delacour JEffects of aging on p- and m-octopamine, catecholamines, and their metabolizing enzymes in the ratJ Neurochem.(1989 Jul)
    66.^Haller CA1, Benowitz NL, Jacob P 3rdHemodynamic effects of ephedra-free weight-loss supplements in humansAm J Med.(2005 Sep)